House committee adds pharma ‘bad actor’ provision to FDA user fee bill

A House subcommittee added an amendment taking aim at rising drug prices to the FDA fee schedule reauthorization bill, but some observers say it will do little to curb abusive pricing of off-patent branded drugs.